Humanigen Inc Quick Ratio (HGEN) starting from the first quarter 2023 to first quarter 2022, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket
 


Humanigen Inc  (NASDAQ: HGEN)

Humanigen Inc's Quick Ratio

HGEN's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Regardless of the sequential decrease in Current Liabilities, during the first quarter 2023, Quick Ratio deteriorated to 0.06 below Humanigen Inc's average Quick Ratio.

Within Major Pharmaceutical Preparations industry 611 other companies have achieved higher Quick Ratio than Humanigen Inc in first quarter 2023. While Quick Ratio total ranking in the first quarter 2023 has deteriorated compared to the prior quarter from 3440 to 5299.

Explain Quick Ratio?
How much Cash & cash equivalents HGEN´s has?
What are HGEN´s Current Liabilities?




HGEN Quick Ratio (Mar 31 2023)
Q1
(Dec 31 2022)
Q4
(Sep 30 2022)
Q3
(Jun 30 2022)
Q2
(Mar 31 2022)
Q1
Y / Y Current Liabilities Change -25.13 % -18.23 % 11.17 % 53.02 % 33.66 %
Y / Y Cash & cash equivalent Change -95.51 % -85.5 % -67.68 % -60.97 % -25.78 %
Quick Ratio MRQ 0.06 0.18 0.32 0.61 0.97
HGEN's Total Ranking # 5299 # 3440 # 3498 # 2738 # 2195
Seq. Current Liabilities Change -5.16 % -26.44 % -0.78 % 8.16 % 3.57 %
Seq. Cash & cash equivalent Change -69.51 % -58.93 % -47.45 % -31.77 % -1.53 %



Quick Ratio first quarter 2023 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 612
Healthcare Sector # 1188
Overall Market # 5299


Quick Ratio Statistics
High Average Low
10.8 2.31 0.01
(Jun 30 2012)   (Mar 31 2020)




Financial Statements
Humanigen Inc's Current Liabilities $ 53 Millions Visit HGEN's Balance sheet
Humanigen Inc's Cash & cash equivalent $ 3 Millions Visit HGEN's Balance sheet
Source of HGEN's Sales Visit HGEN's Sales by Geography


Cumulative Humanigen Inc's Quick Ratio

HGEN's Quick Ratio for the trailling 12 Months

HGEN Quick Ratio

(Mar 31 2023)
12 Months
(Dec 31 2022)
12 Months
(Sep 30 2022)
12 Months
(Jun 30 2022)
12 Months
(Mar 31 2022)
12 Months
Y / Y Current Liabilities TTM Growth 1.52 % 16.49 % 53.27 % 107.7 % 163.77 %
Y / Y Cash & cash equivalent TTM Growth -74.7 % -58.08 % -41.08 % -29.55 % 14.37 %
Quick Ratio TTM 0.32 0.54 0.72 0.92 1.3
Total Ranking TTM # 4611 # 4212 # 1921 # 2163 # 2014
Seq. Current Liabilities TTM Growth -6.37 % -4.27 % 2.69 % 10.3 % 7.44 %
Seq. Cash & cash equivalent TTM Growth -43.65 % -28.41 % -19.72 % -21.87 % -6.65 %


On the trailing twelve months basis In spite of the year on year decrease in HGEN's Current Liabilities to $53.30 millions, cumulative Quick Ratio to 0.32 below the HGEN average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 597 other companies have achieved higher Quick Ratio than Humanigen Inc. While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the fourth quarter 2022 from 4212 to 4611.

Explain Quick Ratio?
How much Cash & cash equivalents HGEN´s has?
What are HGEN´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 598
Healthcare Sector # 1186
Within the Market # 4611


trailing twelve months Quick Ratio Statistics
High Average Low
5.78 1.49 0.03
(Sep. 30, 2014)   (Mar 31 2020)




Companies with similar Quick Ratio in the quarter ending Mar 31 2023, within Major Pharmaceutical Preparations Industry Quick RatioMar 31 2023 MRQ Cash & cash equivalentMar 31 2023 MRQ Current Liabilities
Zyversa Therapeutics Inc   0.15 $ 1.325  Millions$ 8.578  Millions
Accustem Sciences Inc   0.15 $ 0.181  Millions$ 1.194  Millions
Scopus Biopharma Inc   0.15 $ 1.401  Millions$ 9.313  Millions
Northwest Biotherapeutics Inc  0.14 $ 6.191  Millions$ 44.708  Millions
Biolinerx Ltd   0.14 $ 4.255  Millions$ 30.852  Millions
Protokinetix Incorporated  0.13 $ 0.007  Millions$ 0.053  Millions
Celularity Inc   0.13 $ 8.532  Millions$ 66.458  Millions
Takeda Pharmaceutical Company Limited  0.12 $ 3,919.815  Millions$ 31,529.984  Millions
Cv Sciences Inc   0.11 $ 0.714  Millions$ 6.253  Millions
Nls Pharmaceutics Ltd  0.11 $ 0.898  Millions$ 7.920  Millions
Innovation1 Biotech Inc   0.11 $ 0.262  Millions$ 2.335  Millions
Nascent Biotech Inc   0.11 $ 0.172  Millions$ 1.551  Millions
NIKA PHARMACEUTICALS, INC  0.11 $ 0.005  Millions$ 0.041  Millions
Dr Reddy s Laboratories Limited  0.10 $ 103.000  Millions$ 1,044.000  Millions
China Pharma Holdings Inc  0.10 $ 1.167  Millions$ 11.922  Millions
Viatris Inc   0.08 $ 506.600  Millions$ 6,108.100  Millions
Supernus Pharmaceuticals inc   0.08 $ 58.442  Millions$ 731.545  Millions
Athersys Inc  0.08 $ 3.121  Millions$ 39.683  Millions
Lifecore Biomedical Inc   0.08 $ 2.950  Millions$ 37.673  Millions
Aeon Biopharma inc   0.08 $ 0.457  Millions$ 5.873  Millions
Nabriva Therapeutics Plc  0.06 $ 1.798  Millions$ 27.998  Millions
Biofrontera Inc   0.06 $ 1.300  Millions$ 20.450  Millions
Lannett Company Inc  0.06 $ 46.540  Millions$ 733.079  Millions
REST EZ Inc.  0.06 $ 0.003  Millions$ 0.042  Millions
American Bio Medica Corporation  0.06 $ 0.068  Millions$ 1.117  Millions
Humanigen Inc  0.06 $ 3.096  Millions$ 53.296  Millions
Regenerx Biopharmaceuticals inc   0.06 $ 0.102  Millions$ 1.800  Millions
Aditxt Inc   0.05 $ 0.303  Millions$ 5.910  Millions
Cdt Equity Inc   0.05 $ 0.091  Millions$ 1.958  Millions
Procaps Group S a   0.04 $ 17.514  Millions$ 401.651  Millions

Date modified: 2026-09-18T13:11:05+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.